New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
15:26 EDTEXPR, DELL, GMCR, CELG, NYCBStocks with expanding option implied volatility; EXPR DELL GMCR CELG NYCB
News For EXPR;DELL;GMCR;CELG;NYCB From The Last 14 Days
Check below for free stories on EXPR;DELL;GMCR;CELG;NYCB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 24, 2014
07:41 EDTCELGCelgene reports Q1 REVLIMID sales $1.14B
The company said, "REVLIMID sales for the Q1 increased 14% to $1.14B and were driven by overall market share, increased duration of therapy and geographic expansion. U.S. sales of $642M and International sales of $502M increased 13% and 16%, respectively. ABRAXANE sales for Q1 were $185M, a 51% increase. U.S. sales of $142M and International sales of $43M increased 51% and 49%, respectively. The increase in sales reflects the impact of the ongoing U.S. launch in pancreatic cancer and early launch success for pancreatic cancer in Europe."
07:40 EDTCELGCelgene reaffirms 2014 adjusted EPS, sales guidance
Subscribe for More Information
07:40 EDTCELGCelgene sees 2014 adjusted EPS $7.00-$7.20, consensus $7.29
Subscribe for More Information
07:38 EDTCELGCelgene reports Q1 adjusted EPS $1.67, consensus $1.65
Subscribe for More Information
April 23, 2014
16:44 EDTCELGAcceleron, Celgene announce interim clinical data for sotatercept
Subscribe for More Information
15:35 EDTCELGNotable companies reporting before tomorrow's open
Subscribe for More Information
12:38 EDTGMCREarnings Preview: Starbucks sees FY14 EPS growth 18%-22%, revenue growth of 10%
Starbucks (SBUX) is scheduled to report second quarter results after the market close on Thursday, April 24, with a conference call scheduled for 5:00 pm ET. Starbucks purchases and roasts whole bean coffees and sells them, along with brewed coffees, Italian-style espresso beverages, cold blended beverages, food items, teas, and beverage-related accessories and equipment, primarily through company-operated retail stores. EXPECTATIONS: Analysts are looking for earnings per share of 56c on revenue of $3.95B, according to First Call. The consensus range for EPS is 54c-60c on revenue of $3.91B-$4.05B. LAST QUARTER: Starbucks reported first quarter EPS of 71c against estimates for 69c on revenue of $4.2B against estimates for $4.29B. Starbucks said global comparable store sales increased 5%, driven by a 4% increase in traffic. Looking ahead, the company forecast Q2 EPS 54c-55c, third quarter EPS 64c-66c, fourth quarter EPS 70c-75c and fiscal year 2014 EPS $2.59-$2.67 against estimates of $2.66. Starbucks sees FY14 revenue growth of 10% or greater against estimates for $16.57B and sees FY14 global comparable store sales growth in the mid single digits. NEWS: In its Q1 earnings report, Starbucks forecast consolidated operating margin improvement of approximately 150-200 basis points in FY13 over the previous fiscal year. The company said it planned to add approximately 1,500 net new stores in 2014. During the quarter, Starbucks said that Chief Executive Officer Howard Schultz would focus on innovations in coffee and tea, as well as various technology and loyalty initiatives, while the day-to-operations of the company would be overseen by Troy Alstead, who was promoted to a newly created Chief Operating Officer role from the Chief Financial Officer role. Starbucks senior VP of Corporate Finance, Scott Maw, was promoted to executive VP and Chief Financial Officer. The company recently forecast FY14 EPS growth of 18%-22% on revenue growth of 10%. The company is targeting 15%-20% long-term EPS growth. At the company's annual meeting of shareholders, Schultz said he believes Starbucks is "at least" a $100B market capitalization company and that the company is in the "early innings of growth." Alstead said China and Asia Pacific is the company's fastest-growing region. During the quarter, Starbucks amended its agreement with Keurig Green Mountain (GMCR) and partnered with Oprah Winfrey for tea. Globes reported that Starbucks is in advanced talks to buy a 10% stake in SodaStream (SODA) at a company value of $1.1B. STREET RESEARCH: Buckingham views the deal with Keurig Green Mountain as a "positive event," as it provides Starbucks an opportunity for better margins. Piper Jaffray sees "virtually no risk" to Starbucks from higher coffee prices as the company is locked through the first quarter of 2015. Morgan Stanley said weakness in Starbucks due to concerns of decelerating comps and higher coffee prices is overdone. Oppenheimer believes that the recent increases in coffee prices are "manageable" for Starbucks, but have "put a major strain" on its ability to outperform 2015 expectations. PRICE ACTION: Over the last three months, Starbucks shares are down over 3.5%. Year-to-date, shares are down almost 10%
11:51 EDTGMCRDr Pepper Snapple says 'pleased' with Keurig Green Mountain deal
Subscribe for More Information
07:41 EDTCELGAlliqua to launch Biovance human amniotic membrane allograft product
Alliqua (ALQA) will launch its Biovance human amniotic membrane allograft product. Biovance was originally developed by, and is currently being manufactured through a supply agreement with, Celgene Cellular Therapeutics, a subsidiary of Celgene (CELG), to assist wound care specialists, physicians and nurses, as well as vascular, plastic and general surgeons, in the treatment of a wide variety of complex, acute, chronic, recalcitrant, full and partial thickness wound types. With the right to develop and market Biovance, Alliqua has entered into one of the fastest-growing areas of wound care, which involves regenerative medicine. Alliqua will commence sales of Biovance immediately following the Symposium via its team of direct sales representatives.
April 22, 2014
14:28 EDTGMCRSunEdison, Conn's rally after Greenlight discloses new stakes
Subscribe for More Information
07:40 EDTCELGCelgene weakness has created attractive entry point, says Stifel
Subscribe for More Information
April 17, 2014
15:53 EDTGMCRLuigi Lavazza S.p.A confirms 8% stake in Keurig Green Mountain
Subscribe for More Information
April 16, 2014
10:49 EDTGMCRSodaStream rallies following report of talks to sell stake to American company
Subscribe for More Information
08:34 EDTCELGPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 15, 2014
10:07 EDTGMCRCoca-Cola sees 'significant' currency headwinds for the remainder of this year
Subscribe for More Information
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
April 10, 2014
11:31 EDTEXPROptions with increasing implied volatility: EXPR NEE
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use